Drugs / SmofKabiven
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT01362582 | Mar 2010 → Aug 2014 | malignant pancreatic neoplasm | National Center for Tumor Diseases, Heidelberg | Terminated | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT06089551 | Oct 2023 → Oct 2025 | intestinal obstruction, ischemic bowel disorder | Copenhagen University Hospital at Herlev | Unknown | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT01533766 Comparator | Aug 2011 → Jan 2012 | — | JW Life Science | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SMOFKabiven | “SMOFKabiven® will be given over night with a content of 1100 kcal in 986 ml.” NCT01362582 ↗ |
| Route | Intravenous | “intravenously over 5 days infusion” NCT01533766 ↗ |